News

Categories

January 4, 2024

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

January 4, 2024

Zymeworks Announces Additional Leadership Appointments

December 26, 2023

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

December 15, 2023

Zymeworks Added to Nasdaq Biotechnology Index

December 8, 2023

Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023

November 30, 2023

Zymeworks Announces Participation in Upcoming Investor Conference

November 7, 2023

Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results

November 4, 2023

Zymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference

November 1, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

October 20, 2023

Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress

October 17, 2023

Zymeworks To Host Third Quarter 2023 Results Conference Call

October 16, 2023

Zymeworks Announces New Director Nominee